Biotechs Unhinged by Tough Pricing Talk

Biotechs Unhinged-Roiled by Commentary and Tweet storms Biotech stocks rallied briefly early in the week but sold off abruptly over the past two days with a quote from Trump in a Time Person of the Year article as saying, “I’m going to bring down drug prices”. This tough talk is reminiscent of comments by both […]

Continue Reading 0

Market Reversal in Biotech But Healthcare Stocks Are Still Muddled

Market Reversal in Biotech Offers Bullish Set-Up After one of the worst down days in months yesterday biotech stocks broadly reversed today giving a short term “nibble” signal. The macro environment got support from economic data as well with upward Q3 GDP revisions to 3.2% and higher consumer confidence data. The economy now has the […]

Continue Reading 0

Alert: Alzheimer’s Drug Fails in Clinical Trial-Stocks Sink: ACIU,BIIB,LLY…Update-1

Another clinical trial failure for an Alzheimer’s Disease in a late stage trial triggered a pre-market sell-off.  Both Biogen (BIIB) -aducanumab- and Lilly (LLY)- solanezumab -drugs in development are engineered antibodies that attack beta amyloid targets in the brain. At the close 11/23: ACIU $11.53 down 15.84% BIIB $305.93 down 3.83% LLY $68 down 10.51% […]

Continue Reading 0

Rayno Biobeat #4: Sector Shift Underway but what’s next for biotech?…Update-1

Update-1 November 28 Another nasty day for biotech A bit of a selloff in the market indices today with the NASDAQ down 0.58% and the S&P down 0.53%. The highly touted Russell 2000 (IWM) was down 1.3% after a 15 day rally. But the real wreck was in biotech with the XBI down 3.09% and […]

Continue Reading 0

Trump Biotech Rally: After Comey Sell-Off and Since Election

  Trump Biotech Rally-Have a Balanced Portfolio Everybody who invests in biotech knows there has been a Trump biotech rally since his election as you can see from the chart and data below. Many opinions and analysis were given for the rally.Some pundits say it is because the end of the grueling election has removed […]

Continue Reading 0

Rayno Biobeat #3…Trump Biotech Rally Leads Market Up

Trump Election Win Drives Huge Biotech Rally NASDAQ up over 1% to 5248 The Trump biotech rally began at today’s opening up (IBB) 20 points to $280 then held to close  up 8.9% to $285. The XBI soared 10.4% to close at $63.8 near highs of day. The cloud of drug pricing concerns vanished because […]

Continue Reading 0

Rayno Biobeat #2…Good Value in Large Cap Biopharmaceuticals- Update-1

Which Large Cap Biopharma Stocks Have the Best Value? But revenue growth is slowing so M&A must pick up. Drug stocks have gone through a severe correction and healthcare is one of the worse sectors YTD. Although the key indicators are still sketchy, now is the time to look for value among several top large […]

Continue Reading 0

Rayno Biobeat #1… Hot Biotech Stocks: Searching for Clues in a Chaotic Market

Rayno Life Science… Special Report #1: Hot Biotech Stocks in 2016 Biotech stocks have been in a funk for most of 2016 and then got absolutely crushed in October. The underlying causes are well-known among them bad news from bad actors like Mylan and  Turing, the populist revolt against high drug prices and lackluster top […]

Continue Reading 0

Biotech Meltdown: Financial Metrics Offer Few Clues For What is Next

Biotech Meltdown: Numbers Don’t Mean Much Until We See New Product Growth We are almost through the earnings season and despite good results most biotech stocks tanked again today.The reason you know well by now-expectations for earnings and top line growth have been taken down because price increases are not likely for 2017 . Another […]

Continue Reading 0

Biotech Bear Market Looking For Relief From Q3 Large Cap Growth…Update-3

Update-3… 10/28 9:30 am… No Relief From Earnings- Biotech Stocks Get Crushed By More Pricing Commentary on Earnings Calls Amgen (AMGN) down 11% on pipeline, revenue growth, Enbrel pricing concerns despite beat. Softer pricing environment from McKesson (MCK). All large caps are red except Alexion (ALXN) up 1.83%. Abbvie (ABBV) down 6% on revenue miss;Humira […]

Continue Reading 0